ADAnna Drużdżel

Anna Drużdżel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Drużdżel has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of air pollution on otolaryngological disease

    by Zuzanna Parfienowicz, Anna Drużdżel, Marta Krzyżanowska, Kacper Curzytek

    Introduction and objective: Air pollution is a major environmental health problem associated with increased respiratory morbidity and mortality. Pollutants such as particulate matter (PM2,5, PM10), nitrogen dioxide, sulpher dioxide, ozone, and carbon monoxide may damage the...

  • Open Access

    The Role of Vitamin D in Inflammatory Bowel Disease: Clinical Relevance and Therapeutic Potential

    by Anna Drużdżel, Natalia Pawelec, Weronika Mazur, Marta Krzyżanowska, Kacper Curzytek, Zuzanna Parfienowicz

    Background:Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is characterized by chronic relapsing inflammation of the gastrointestinal tract. Increasing evidence suggests that vitamin D plays an important role in immune regulation and intestinal barrier integrity. Aim:The aim of this review was to evaluate the clinical relevance of serum vitamin D levels in patients with inflammatory bowel disease and to assess the potential role of vitamin D supplementation. Material and methods: A narrative review of current literature concerning vitamin D and IBD was conducted using clinical studies, systematic reviews, meta-analyses, and experimental studies retrieved from databases including PubMed and Scopus. Results: Vitamin D deficiency is highly prevalent among patients with IBD and has been associated with increased disease activity, higher inflammatory burden, greater risk of relapse and poorer quality of life. Low serum 25(OH)D levels correlate with inflammatory markers such as C-reactive protein and fecal calprotectin. Experimental and clinical studies suggest that vitamin D influences intestinal inflammation through modulation of immune responses, maintenance of epithelial barrier function, and regulation of gut microbiota. Available evidence indicates that vitamin D supplementation may improve selected clinical outcomes, particularly in patients with Crohn’s disease in remission, although current data remain heterogeneous. Conclusions:Vitamin D appears to be a clinically relevant and modifiable factor in IBD management. Routine assessment and correction of vitamin D deficiency may represent a useful adjunct to standard therapy; however, further randomized controlled trials are required to establish optimal supplementation strategies.

  • Open Access

    The oral exposome – integrating environmental determinants into the etiology of oral pathologies

    by Marta Krzyżanowska, Anna Drużdżel, Zuzanna Parfienowicz, Kacper Curzytek, Maciej Szczupaj

    Introduction: Oral diseases remain a major global health challenge, affecting app. 3.5 billion people. While traditional etiological models have focused primarily on behavioural and microbial factors, the disproportionate disease burden in industrializing regions suggests the presence of...


  • Open Access

    EXPLORING THE POTENTIAL ROLE OF OMEGA-3 FATTY ACIDS IN DEPRESSION

    by Natalia Pawelec, Weronika Mazur, Edyta Hańczyk, Dawid Piecuch, Szymon Kopciał, Karolina Kornatowska, Anna Drużdżel

    Introduction: Depression represents a major public health challenge, affecting individuals worldwide and remaining a prevalent condition that significantly reduces quality of life. Despite the availability of various therapeutic options, including pharmacological interventions, these treatments are often insufficiently effective. Consequently, the search for safe and effective strategies to alleviate depressive symptoms remains a priority. Numerous studies have examined the potential role of omega-3 fatty acids in both the prevention and treatment of depression. In this context, the involvement of inflammatory processes and stress-related pathophysiological mechanisms appears to be particularly relevant. Therefore, research continues to investigate the potential relationship between omega-3 fatty acid supplementation and clinical improvement in patients with depression. Aim of Study: The purpose of this review is to explore potential novel therapeutic strategies that may benefit patients with depression. Material and methods: This narrative review synthesizes contemporary evidence regarding the role of omega-3 fatty acids in the prevention and treatment of depressive disorders. A targeted literature search was conducted using PubMed and Google Scholar. The search was focused primarily on studies published within the five-ten years. Search terms included combinations of “omega-3 fatty acids,” “eicosapentaenoic acid,” “docosahexaenoic acid,” “major depressive disorder,” “treatment-resistant depression". Randomized controlled trials, clinical trials, meta-analyses, systematic reviews, and high-quality narrative reviews were prioritized. Consistent with the narrative nature of this review, no formal systematic screening protocol, risk-of-bias assessment, or quantitative synthesis was performed. Results and Conclusions: After examining the effects of omega-3 fatty acids in patients across different age groups, both as monotherapy and in combination with other agents, including postpartum women, studies have not produced conclusive evidence directly supporting their beneficial impact on depression.

  • Open Access

    Persistent Cognitive Dysfunction Following Systemic Chemotherapy in Women with Breast Cancer

    by Weronika Mazur, Natalia Pawelec, Edyta Hańczyk, Dawid Piecuch, Szymon Kopciał, Karolina Kornatowska, Anna Drużdżel

    Chemotherapy-related cognitive impairment (CRCI), commonly known as “chemobrain,” is a prevalent and clinically significant complication in breast cancer survivors. Cognitive deficits primarily affect memory, attention, executive function, processing speed, and verbal fluency, and may persist for months to years after treatment. CRCI arises from multiple mechanisms, including direct neurotoxicity, neuroinflammation, oxidative stress, mitochondrial dysfunction, hormonal alterations, genetic susceptibility, psychosocial stressors, and gut–brain axis changes. Neuroimaging studies demonstrate structural and functional brain alterations such as gray matter reduction, white matter microstructural changes, disrupted connectivity, and compensatory cortical hyperactivation, particularly within frontoparietal and temporal networks. Subjective cognitive complaints often correspond with objective deficits, although considerable heterogeneity exists. Precision approaches, including machine learning-based neuroimaging biotyping and multimodal cognitive assessment, enable identification of biologically distinct subgroups and improve risk stratification. Non-pharmacological interventions such as cognitive rehabilitation, physical activity, mindfulness, and psychosocial support have shown efficacy, whereas pharmacological options remain limited. Integrating biological, neuroimaging, genetic, and psychosocial data is essential for developing individualized strategies to preserve cognitive function and quality of life. Future research should prioritize longitudinal studies, biomarker discovery, ecological cognitive monitoring, and digital therapeutics to optimize precision survivorship care.

  • Open Access

    CLINICAL PRESENTATION OF LEFT VENTRICULAR NONCOMPACTION DIAGNOSED IN ADULTS

    by Kacper Curzytek, Marcelina Podleśna, Karol Chromiak, Aleksandra StęPień, Kacper Bączek, Kacper Bluczak, Marta Krzyżanowska, Anna Drużdżel, Zuzanna Parfienowicz, Katarzyna Czechowicz

    Left ventricular noncompaction (LVNC) is a rare, morphologically and genetically heterogeneous form of cardiomyopathy, the pathogenesis, classification, and clinical significance of which remain subjects of ongoing debate. The aim of this review is to present the current state of knowledge regarding the classification, pathophysiology, diagnostics, genetic determinants, clinical presentation, and therapeutic management of LVNC. The European Society of Cardiology (ESC) classifies LVNC as an unclassified cardiomyopathy, whereas the American Heart Association (AHA) considers it a genetically determined cardiac disorder. The characteristic morphology arises from abnormal compaction of the left ventricular trabeculae during embryogenesis, although an acquired or adaptive origin of these changes is also possible. Diagnostic evaluation relies primarily on echocardiography and cardiac magnetic resonance imaging; however, the lack of uniform morphological criteria contributes to both overdiagnosis and underdiagnosis. From a genetic perspective, sarcomeric gene mutations predominate and are associated with more severe clinical outcomes. Clinical manifestations include heart failure, arrhythmias, and thromboembolic complications, with reduced left ventricular ejection fraction being the principal prognostic factor. Therapeutic management follows general heart failure treatment strategies, thromboembolism prevention, and implantation of cardiac devices; in advanced cases, heart transplantation or mechanical circulatory support may be considered. An integrated diagnostic approach and the MOGE(S) classification system may serve as a foundation for future standardization.